Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Santen Pharmaceutical acquires 50.55% of Novagali Pharma

Executive Summary

Japanese pharmaco Santen Pharmaceutical Co. Ltd. has agreed to buy 50.55% of French ophthalmic therapeutics developer Novagali Pharma SA for €50.7mm ($69.5mm) in cash, or about €6.15 per share (a 77% premium). After the initial transaction, Santen will purchase the remaining shares for the same price; if it acquires at least 95% of Novagali, the price will be increased to €6.25.
Deal Industry
  • Biotechnology
  • Medical Devices
  • Pharmaceuticals
  • Pharmaceuticals
    • Drug Delivery
      • Site Specific
      • Topical Delivery
Deal Status
  • Final
Deal Type
  • Acquisition
    • Partial Acquisition
    • Payment Includes Cash

Related Companies